Viatris Inc.
Fundamentals are temporarily unavailable for VTRS.
| USD | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $16.26B | $15.43B | $14.74B | $14.30B |
| Cost of Revenue | $9.77B | $8.99B | $9.12B | $9.29B |
| Gross Profit | $6.50B | $6.44B | $5.62B | $5.01B |
| Research & Development | $662.20M | $805.20M | $808.70M | $965.90M |
| Selling, General & Admin | $4.18B | $4.07B | $4.10B | $3.79B |
| Operating Expenses | $4.84B | $4.88B | $4.91B | $4.76B |
| Operating Income | $1.66B | $1.56B | $710.30M | $253.50M |
| EBITDA | $6.43B | $3.52B | $2.82B | -$395.40M |
| Pretax Income | $2.81B | $202.90M | -$623.20M | -$3.67B |
| Income Tax | $734.60M | $148.20M | $11.00M | -$150.10M |
| Net Income | $2.08B | $54.70M | -$634.20M | -$3.51B |
| Diluted EPS | 1.71 | 0.05 | -0.53 | -3.00 |
| Diluted Shares | 1.22B | 1.21B | 1.19B | 1.17B |
| USD | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Cash & Equivalents | $1.26B | $991.90M | $734.80M | $1.32B |
| Receivables | $4.14B | $4.04B | $3.52B | $3.35B |
| Inventory | $3.52B | $3.47B | $3.85B | $4.00B |
| Current Assets | $10.64B | $12.98B | $9.52B | $9.79B |
| Total Assets | $50.02B | $47.69B | $41.50B | $37.19B |
| Current Liabilities | $6.75B | $7.78B | $5.78B | $7.09B |
| Long-Term Debt | $18.02B | $16.19B | $14.04B | $12.48B |
| Total Debt | $19.53B | $18.37B | $14.31B | $14.70B |
| Total Liabilities | $28.95B | $27.22B | $22.87B | $22.48B |
| Retained Earnings | $5.18B | $4.64B | $3.42B | -$388.30M |
| Shareholders' Equity | $21.07B | $20.47B | $18.64B | $14.71B |
| Working Capital | $3.89B | $5.20B | $3.74B | $2.69B |
| Net Debt | $18.01B | $17.13B | $13.30B | $13.09B |
| USD | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Operating Cash Flow | $3.00B | $2.90B | $2.30B | $2.32B |
| Capital Expenditure | -$489.40M | -$574.90M | -$359.10M | -$465.10M |
| Free Cash Flow | $2.51B | $2.33B | $1.94B | $1.85B |
| Depreciation & Amortisation | $3.03B | $2.74B | $2.89B | $2.80B |
| Stock-Based Compensation | $116.40M | $180.70M | $146.10M | $177.70M |
| Investing Cash Flow | $1.47B | -$864.50M | $1.80B | -$427.70M |
| Financing Cash Flow | -$3.88B | -$2.30B | -$4.33B | -$1.29B |
| Dividends Paid | -$581.60M | -$575.60M | -$574.80M | -$561.20M |
| Share Repurchases | $0.00 | -$250.00M | -$250.00M | -$500.50M |
| Net Change in Cash | $595.20M | -$266.40M | -$226.80M | $594.30M |
| USD | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|
| Revenue | $3.25B | $3.58B | $3.76B | $3.70B | $3.52B | $3.76B |
| Cost of Revenue | $2.09B | $2.25B | $2.39B | $2.56B | $2.36B | $2.30B |
| Gross Profit | $1.16B | $1.33B | $1.37B | $1.15B | $1.16B | $1.46B |
| Research & Development | $222.00M | $218.80M | $250.40M | $274.70M | $248.60M | $248.30M |
| Selling, General & Admin | $948.10M | $928.70M | $886.60M | $1.03B | $928.80M | $1.13B |
| Operating Expenses | $1.17B | $1.15B | $1.14B | $1.31B | $1.18B | $1.38B |
| Operating Income | -$8.90M | $185.40M | $234.50M | -$157.50M | -$20.20M | $73.70M |
| EBITDA | -$2.32B | $577.80M | $800.20M | $543.40M | $548.90M | $729.00M |
| Pretax Income | -$3.10B | -$217.10M | -$7.90M | -$343.00M | -$247.30M | -$64.00M |
| Income Tax | -$55.00M | -$212.50M | $120.30M | -$2.90M | -$423.70M | $54.80M |
| Net Income | -$3.04B | -$4.60M | -$128.20M | -$340.10M | $176.40M | -$118.80M |
| Diluted EPS | -2.55 | 0.00 | -0.11 | -0.30 | 0.15 | -0.10 |
| Diluted Shares | 1.19B | 1.17B | 1.16B | 1.15B | 1.18B | 1.16B |
| USD | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $755.00M | $566.40M | $975.30M | $1.32B | $1.80B | $886.50M |
| Receivables | $3.39B | $3.60B | $3.59B | $3.35B | $3.74B | $3.67B |
| Inventory | $4.10B | $4.26B | $4.11B | $4.00B | $3.93B | $3.93B |
| Current Assets | $9.62B | $9.77B | $9.95B | $9.79B | $10.92B | $10.06B |
| Total Assets | $38.47B | $38.41B | $37.92B | $37.19B | $36.83B | $35.04B |
| Current Liabilities | $5.72B | $7.13B | $7.36B | $7.09B | $6.81B | $6.35B |
| Long-Term Debt | $14.18B | $12.79B | $12.49B | $12.48B | $12.41B | $11.61B |
| Total Debt | $14.46B | $14.76B | $14.72B | $14.70B | $14.61B | $13.63B |
| Total Liabilities | $22.82B | $22.84B | $22.70B | $22.48B | $22.18B | $20.78B |
| Retained Earnings | $227.90M | $80.00M | -$48.20M | -$388.30M | -$211.90M | -$330.70M |
| Shareholders' Equity | $15.65B | $15.57B | $15.22B | $14.71B | $14.66B | $14.26B |
| Working Capital | $3.90B | $2.64B | $2.59B | $2.69B | $4.11B | $3.71B |
| Net Debt | $13.42B | $13.90B | $13.46B | $13.09B | $12.54B | $12.46B |
| USD | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $535.50M | $219.70M | $744.90M | $815.80M | $388.30M | $381.80M |
| Capital Expenditure | -$76.40M | -$54.10M | -$99.70M | -$234.90M | -$124.20M | -$59.80M |
| Free Cash Flow | $459.10M | $165.60M | $645.20M | $580.90M | $264.10M | $322.00M |
| Depreciation & Amortisation | $664.70M | $678.30M | $688.50M | $766.80M | $676.10M | $672.30M |
| Stock-Based Compensation | $55.20M | $37.10M | $36.00M | $49.40M | $48.20M | $38.70M |
| Investing Cash Flow | -$65.10M | -$52.50M | -$98.90M | -$211.20M | $277.40M | -$51.60M |
| Financing Cash Flow | -$467.00M | -$362.40M | -$228.10M | -$236.40M | -$203.80M | -$1.24B |
| Dividends Paid | -$143.30M | -$139.80M | -$139.90M | -$138.20M | -$139.60M | -$139.80M |
| Share Repurchases | -$175.40M | -$175.00M | -$65.00M | -$85.10M | $0.00 | -$150.00M |
| Net Change in Cash | $3.40M | -$195.20M | $417.90M | $368.20M | $461.90M | -$912.40M |
Market Snapshot
About
Viatris is a global healthcare company formed through the merger of Mylan and Upjohn, a division of Pfizer. The company focuses on developing, manufacturing, and distributing generic and branded pharmaceutical products across a wide range of therapeutic categories. Viatris serves patients in more than 165 countries with a mission to expand access to quality medicines worldwide.